Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer

Silwan Chedid, Edgardo Rivera, Debbie K. Frye, Nuhad Ibrahim, Francisco Esteva, Vicente Valero, Gabriel Hortobagyi, Karl L. Mettinger, Massimo Cristofanilli

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer'. Together they form a unique fingerprint.

INIS

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology